Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

ANNOUNCEMENT
(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 20 NOVEMBER 2026; AND
(2) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(3) CHANGES IN COMPOSITION OF BOARD COMMITTEES

POLL RESULTS OF THE EGM

The Board is pleased to announce that all resolutions as set out in the Notice dated 2 November 2026 were duly passed by way of poll by the Shareholders at the EGM held on Friday, 20 November 2026.

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Dr. Pan Guangjin has been appointed as an independent non-executive Director with effect from 20 November 2026 following the approval of his appointment by the Shareholders at the EGM.

The Board also announces that the resignation of Prof. Jin Tengchuan as an independent non-executive Director has become effective upon the conclusion of the EGM following the approval of the appointment of Dr. Pan as an independent non-executive Director by the Shareholders at the EGM.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

Following the appointment of Dr. Pan as an independent non-executive Director, the Board announces that, with effect from 20 November 2026, he has also been appointed, in place of Prof. Jin, as the chairman of the Nomination Committee and a member of each of the Audit Committee and the Remuneration Committee.

The Board also announces that, with effect from 20 November 2026, Ms. Kang Rui has been appointed as a member of the Nomination Committee.

References are made to (i) the announcement of Biosino Bio-Technology and Science Incorporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 30 October 2026 (the "**Announcement**") and the circular of the Company dated 2 November 2026 (the "**Circular**") in relation to, among other things, the proposed change of independent non-executive Director; and (ii) the notice (the "**Notice**") of the extraordinary general meeting (the "**EGM**") dated 2 November 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement and the Circular, as the case may be.

POLL RESULTS OF THE EGM

The EGM was held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Friday, 20 November 2026. The Board is pleased to announce that all the resolutions as set out in the Notice were duly passed at the EGM. As at the date of the EGM, the Company issued a total of 144,707,176 Shares, comprising 64,286,143 H Shares and 80,421,033 Domestic Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the EGM. There were no Shares entitling the holders thereof to attend and vote only against the resolutions at the EGM. No restriction was imposed on any Shareholder casting votes on any of the proposed resolutions at the EGM. All the resolutions at the EGM were put to the vote by way of poll. BDO China Shu Lun Pan Certified Public Accountants LLP was appointed as the scrutineer at the EGM for the purpose of vote-taking.

The poll results of the respective resolutions at the EGM are as follows:

ORDINARY RESOLUTION		**Number of votes cast and approximate percentage of total number of votes cast**	
		For	**Against**
1.	To consider and approve the appointment of Mr. Pan Guangjin as an independent non-executive Director, and authorise the Board to fix his remuneration and to enter into service agreement with him subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters.	106,806,298 (100%)**	0 (0%)**

SPECIAL RESOLUTION		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
2.	To consider and approve the proposed amendments to the articles of association of the Company.	106,806,298 (100%)**	0 (0%)**

** *The percentage of voting Shares is based on the total number of Shares held by the Shareholders who voted at the EGM in person or by proxy.*

As more than 50% of the total number of Shares held by the Shareholders who voted at the EGM were cast in favour of the resolution no. (1) and more than two-thirds of the total number of Shares held by the Shareholders who voted at the EGM were cast in favour of the resolution no. (2), all the above resolutions were approved by the Shareholders.

Save for Prof. Jin Tengchuan ("**Prof Jin**"), all Directors attended the EGM either in person or by electronic means.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Dr. Pan Guangjin ("**Dr. Pan**") has been appointed as an independent non-executive Director with effect from 20 November 2026 following the approval of his appointment by the Shareholders at the EGM.

Dr. Pan has confirmed that (i) he met the independence criteria as set out in Rule 5.09 of the GEM Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Biographical details of Dr. Pan are as follows:

Dr. Pan Guangjin (潘光錦博士), aged 52, obtained a doctoral degree from the School of Medicine of Tsinghua University in 2005 and completed his postdoctoral research from the University of Wisconsin-Madison in 2008. Dr. Pan has extensive experience in regenerative medicine and stem cell research. Dr. Pan previously worked as an assistant researcher at the University of Wisconsin, a researcher and deputy director of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. He is currently a director of the Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences.

Dr. Pan will enter into a service agreement with the Company. He will be entitled to a fixed director's fee of RMB5,000 per month. His term of service with the Company takes effect from the date of approval by the Shareholders at the EGM until the expiration of the term of the current session of the Board. His remuneration was determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Dr. Pan does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. He does not have, and is not deemed to have any interests or short positions in any Shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. He does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

Save as disclosed above, there are no other matters relating to his appointment that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

The Board wishes to take this opportunity to welcome Dr. Pan for joining the Board.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board also announces that the resignation of Prof. Jin as an independent non-executive Director has become effective upon the conclusion of the EGM following the approval of the appointment of Dr. Pan as an independent non-executive Director by the Shareholders at the EGM.

Prof. Jin has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation as a Director that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its appreciation for the valuable contribution of Prof. Jin towards the Company during his tenure of service.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

Following the appointment of Dr. Pan as an independent non-executive Director, the Board announces that, with effect from 20 November 2026, he has also been appointed, in place of Prof. Jin, as the chairman of the Nomination Committee and a member of each of the Audit Committee and the Remuneration Committee.

The Board also announces that, with effect from 20 November 2026, Ms. Kang Rui has been appointed as a member of the Nomination Committee.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, the PRC, 20 November 2026

As at the date of this announcement, the Board comprises:

Chairman, President and Executive Director
Mr. Chen Peng (陳鵬先生)

Vice Chairman and Executive Director
Mr. Li Zhonghua (李忠華先生)

Executive Director
Mr. Chen Zhengyong (陳正永先生)

Non-executive Director
Ms. Kang Rui (康睿女士)

Independent non-executive Directors
Prof. Shen Jiangang (沈劍剛教授), Mr. Fan Xiaoliang (范曉亮先生) and Dr. Pan Guangjin (潘光錦博士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.zhongsheng.com.cn.